VALID Act of 2023 Verifying Accurate Leading-edge IVCT Development Act of 2023
Impact
The VALID Act is expected to significantly alter the landscape of how in vitro clinical tests are regulated. By creating a separate pathway for these tests, the bill will provide developers a faster, more predictable regulatory framework while still ensuring that safety and effectiveness standards are maintained. This shift is anticipated to foster innovation in the field of medical diagnostic testing, making it easier for new and potentially life-saving technologies to reach patients more swiftly. Additionally, the bill includes provisions for transitioning existing tests to this new framework, ensuring continuity for both manufacturers and patients.
Summary
House Bill 2369, titled the Verifying Accurate Leading-edge IVCT Development Act of 2023 (VALID Act), aims to amend the Federal Food, Drug, and Cosmetic Act concerning in vitro clinical tests. This legislation seeks to introduce a new regulatory framework for these tests, which are crucial for diagnosing, screening, and monitoring diseases. Notably, the bill defines in vitro clinical tests and establishes processes for their approval, including the technology certification order system, which will allow for a more efficient route to market compared to traditional premarket approval processes. The bill is seen as a stride toward modernizing the regulation of diagnostic technologies and addressing the evolving landscape of healthcare innovations.
Contention
However, while proponents of the VALID Act argue that it will enhance patient access to advanced diagnostics, there are concerns regarding the potential risks associated with a fast-tracked regulatory process. Critics argue that prioritizing speed over thoroughness may compromise patient safety, as the robust procedures established for traditional medical devices are not as stringent under the new framework. There are also apprehensions about the implications this bill may have on the quality of data being submitted for regulatory review and how it may affect public trust in medical diagnostics.
Requires that all cosmetics manufactured, sold, delivered, held or offered for sale contain a label that completely and accurately list all of their component ingredients.
Requires that all cosmetics manufactured, sold, delivered, held or offered for sale contain a label that completely and accurately list all of their component ingredients.